GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...

Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare ...

An appeals court has opened another chapter in the long-running CRISPR patent saga. | An appeals court has opened another ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable ...

The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered ...

North Carolina-based CRO Fortrea is saying goodbye to its CEO. | North Carolina-based CRO Fortrea is saying goodbye to its ...

The uncertainty around splitting up the business is only the latest in a series of strategic shake-ups at Galapagos in recent years. Other major events have included the pivot to CAR-Ts in 2022 and ...